Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1048477/000156459018025196/bmrn-10q_20180930.htm
Exhibit 99.1
Contact: |
|
|
Investors: |
|
Media: |
Traci McCarty |
|
Debra Charlesworth |
BioMarin Pharmaceutical Inc. |
|
BioMarin Pharmaceutical Inc. |
(415) 455-7558 |
|
(415) 455-7451 |
BioMarin Announces Third Quarter 2018 Results
- First Nine Months of 2018 Total Revenues Grow 19% Year-over-year to $1.14 Billion
- 124 Commercial Patients Receiving Treatment with Palynziq in First Full Quarter since U.S. Approval
- Vosoritide 42-Month Data; PKU Gene Therapy Preclinical Data and Research Deep Dive
at R&D Day on November 7 in New York City
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||||||||||
|
|
2018 |
|
|
2017 |
|
|
% Change |
|
|
2018 |
|
|
2017 |
|
|
% Change |
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Revenues |
|
$ |
391.7 |
|
|
$ |
334.1 |
|
|
|
17 |
% |
|
$ |
1,138.0 |
|
|
$ |
955.3 |
|
|
|
19 |
% |
Vimizim Net Product Revenues |
|
|
123.3 |
|
|
|
90.3 |
|
|
|
37 |
% |
|
|
368.0 |
|
|
|
299.3 |
|
|
|
23 |
% |
Kuvan Net Product Revenues |
|
|
113.3 |
|
|
|
105.8 |
|
|
|
7 |
% |
|
|
321.4 |
|
|
|
300.1 |
|
|
|
7 |
% |
Naglazyme Net Product Revenues |
|
|
103.1 |
|
|
|
72.1 |
|
|
|
43 |
% |
|
|
269.2 |
|
|
|
238.4 |
|
|
|
13 |
% |
Aldurazyme Net Product Revenues |
|
|
27.6 |
|
|
|
22.4 |
|
|
|
23 |
% |
|
|
117.7 |
|
|
|
61.7 |
|
|
|
91 |
% |
Brineura Net Product Revenues |
|
|
9.9 |
|
|
|
3.1 |
|
|
|
219 |
% |
|
|
27.7 |
|
|
|
3.4 |
|
|
|
715 |
% |
Palynziq Net Product Revenues |
|
|
4.1 |
|
|
|
— |
|
|
n/a |
|
|
|
4.1 |
|
|
|
— |
|
|
n/a |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Net Loss |
|
$ |
(12.6 |
) |
|
$ |
(12.5 |
) |
|
|
|
|
|
$ |
(73.6 |
) |
|
$ |
(65.7 |
) |
|
|
|
|
GAAP Net Loss per Share - Basic and Diluted |
|
$ |
(0.07 |
) |
|
$ |
(0.07 |
) |
|
|
|
|
|
$ |
(0.42 |
) |
|
$ |
(0.38 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Income (1) |
|
$ |
60.7 |
|
|
$ |
7.8 |
|
|
|
|
|
|
$ |
101.8 |
|
|
$ |
68.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
December 31, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
2018 |
|
|
2017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Cash, cash equivalents and investments |
|
$ |
1,648.3 |
|
|
$ |
1,781.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Non-GAAP Income is defined by the Company as reported GAAP Net Income (Loss), excluding net interest expense, provision for (benefit from) income taxes, depreciation expense, amortization expense, stock-based compensation expense, contingent consideration expense and, in certain periods, certain other specified items. Refer to Non-GAAP Information beginning on page 9 of this press release for a complete discussion of the Company’s Non-GAAP financial information and reconciliations to the comparable information reported under Generally Accepted Accounting Principles in the United States (US GAAP). |
1
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Biomarin Pharmaceutical Inc.
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1048477/000156459018025196/bmrn-10q_20180930.htm
Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.
ContinueRead positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.
ContinueRemove data columns and navigations in order to see much more filing content and tables in one view
ContinueRead both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q
ContinueExport Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis
ContinueGet one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports
Continue for FREEOur Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not
ContinueOur Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity
ContinueSee how over 70
Growth, Profitability and Financial Ratios perform over 10 Years